When Were GLP 1 Drugs Approved? A Full Timeline

Introduction

Finding a weight loss solution that actually works can feel like a lifelong search for a missing puzzle piece. Many people spent years trying restrictive diets and intense exercise plans, only to find the scale would not budge or the weight would return immediately. When GLP-1 medications seemingly appeared overnight as a solution for chronic weight management, it may have felt like a sudden discovery. However, the history of these medications stretches back much further than the recent social media buzz.

At TrimRx, we believe that understanding the clinical history of these treatments is essential for anyone considering a medical weight loss journey. These medications were not created in a vacuum; they are the result of decades of research into metabolic health and appetite regulation. This article provides a detailed timeline of when GLP-1 drugs were approved, the scientific evolution of the class, and how they became the foundation of modern weight management programs. If you want to see whether a prescription program fits your profile, you can take the free assessment quiz.

The Early Discovery of GLP-1

Before the first medication could be approved, scientists had to discover the hormone itself. Glucagon-like peptide-1 (GLP-1) is a hormone naturally produced in the small intestine. It plays a vital role in metabolic health by stimulating insulin secretion, slowing down how fast the stomach empties, and signaling the brain that the body is full.

Researchers first identified this hormone in the early 1980s. They realized that it could potentially help people with Type 2 diabetes by managing blood sugar levels in a way that traditional insulin treatments could not. However, natural GLP-1 is broken down by the body in just a few minutes. This meant that for a drug to be effective, scientists had to find a way to make it last longer in the bloodstream.

Key Takeaway: GLP-1 is a natural hormone that regulates hunger and blood sugar, but it took decades of research to turn this biological signal into a stable, long-lasting medication.

That scientific foundation also helped shape later medications like semaglutide, and a useful companion read is what semaglutide injections are and how they can help you.

The First Wave: Diabetes Approvals (2005–2010)

The first GLP-1 receptor agonist—a type of drug that mimics the natural GLP-1 hormone—did not come from a human source. It was based on a protein found in the saliva of the Gila monster, a lizard native to the Southwestern United States. This protein, called exendin-4, acted similarly to human GLP-1 but remained active in the body for much longer.

Exenatide: The Pioneer (2005)

In April 2005, the FDA granted the first-ever approval for a GLP-1 receptor agonist. The medication was exenatide, marketed under the name Byetta. It was approved specifically for the treatment of Type 2 diabetes. At the time, it required two injections per day. While it was a major step forward for blood sugar control, patients also began to notice a secondary effect: they were losing weight. This observation set the stage for the next twenty years of research.

Liraglutide for Diabetes (2010)

The next major milestone occurred in January 2010, when the FDA approved liraglutide, known by the brand name Victoza®. This was a significant advancement because it only required one injection per day instead of two. Like its predecessor, Victoza® was approved to improve glycemic control in adults with Type 2 diabetes. The clinical trials for liraglutide showed even more consistent weight loss results than exenatide, leading researchers to investigate whether a higher dose could be used specifically for obesity.

The First Weight Loss Approval (2014)

For nearly a decade, GLP-1 drugs were used exclusively for diabetes. That changed in December 2014 when the FDA approved Saxenda®, a high-dose version of liraglutide. This was the first GLP-1 medication specifically approved for chronic weight management rather than diabetes.

Saxenda® was indicated for adults with a Body Mass Index (BMI) of 30 or greater, or 27 or greater for those with at least one weight-related condition like high blood pressure. This approval shifted the medical community’s perception of obesity. It began to be treated as a chronic metabolic condition that could be managed with long-term medication, rather than just a lifestyle issue.

Quick Answer: The first GLP-1 drug approved specifically for weight loss was Saxenda® (liraglutide) in December 2014. Prior to that, GLP-1 medications were only approved for treating Type 2 diabetes.

The Semaglutide Revolution (2017–2021)

While liraglutide was effective, the requirement for a daily injection was a barrier for many. Pharmaceutical researchers aimed to create a molecule that lasted even longer in the body. This led to the development of semaglutide, a potent GLP-1 receptor agonist that only needs to be administered once a week.

For a practical walkthrough of starting semaglutide therapy, How Do I Start Taking Ozempic: A Step-by-Step Guide is a helpful next read.

Ozempic® Approval (2017)

In December 2017, the FDA approved Ozempic® (semaglutide) for the treatment of Type 2 diabetes. Because of its once-weekly dosing and high efficacy in lowering A1C levels, it quickly became a preferred option for many healthcare providers. As with previous GLP-1s, the weight loss observed in patients was significant.

Rybelsus®: The First Oral Option (2019)

In September 2019, the FDA approved Rybelsus®, which is an oral tablet version of semaglutide for Type 2 diabetes. This was a technological breakthrough because GLP-1 molecules are typically broken down by stomach acid. The development of a special coating allowed the medication to be absorbed through the stomach lining, offering an alternative for those who preferred not to use injections.

Wegovy®: A Landmark for Weight Management (2021)

The most significant moment for the modern weight loss industry occurred in June 2021. The FDA approved Wegovy®, which is the version of semaglutide specifically indicated for chronic weight management. The clinical trials, known as the STEP trials, showed that participants using semaglutide lost significantly more weight than those using previous generations of GLP-1 drugs.

Wegovy® is approved for adults with obesity or those who are overweight with weight-related medical problems. This approval sparked the massive surge in interest we see today, as the results were comparable to some forms of weight loss surgery for many individuals.

If you are comparing prescription pathways, where to get Wegovy weight loss is a useful companion guide.

The Evolution of Dual Agonists: Tirzepatide (2022–2023)

As semaglutide was gaining popularity, a new class of medication was in development. Scientists discovered that they could achieve even better results by targeting two different hunger-related hormones at once. This led to the creation of tirzepatide, which targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.

Mounjaro® Approval (2022)

In May 2022, the FDA approved Mounjaro® (tirzepatide) for the treatment of Type 2 diabetes. By activating two hormone pathways instead of one, tirzepatide showed unprecedented efficacy in lowering blood sugar and reducing body weight in clinical trials.

If you want to compare the options in this class more closely, what is the best tirzepatide for weight loss? is a useful next read.

Zepbound® Approval (2023)

Following the success of Mounjaro®, the FDA approved the same molecule under a different brand name for weight management. In November 2023, Zepbound® was officially approved for chronic weight management in adults. This represented the latest and most potent addition to the FDA-approved options for medical weight loss.

For a deeper look at longer-term use, can you take tirzepatide forever? offers additional context.

Medication Name	Molecule	FDA Approval Year	Primary Indication
Byetta	Exenatide	2005	Type 2 Diabetes
Victoza®	Liraglutide	2010	Type 2 Diabetes
Saxenda®	Liraglutide	2014	Weight Management
Ozempic®	Semaglutide	2017	Type 2 Diabetes
Rybelsus®	Semaglutide	2019	Type 2 Diabetes (Oral)
Wegovy®	Semaglutide	2021	Weight Management
Mounjaro®	Tirzepatide	2022	Type 2 Diabetes
Zepbound®	Tirzepatide	2023	Weight Management

Understanding Compounded vs. Branded Medications

With the massive demand for semaglutide and tirzepatide, many patients find that branded medications are often on the FDA drug shortage list. This is where compounded medications play a role in the healthcare landscape.

It is important to understand the distinction between these categories. Compounded semaglutide and compounded tirzepatide are not FDA-approved in the same way branded medications are. Instead, they are prepared by licensed, FDA-registered, and inspected compounding pharmacies. These pharmacies create personalized formulations of the medications when the commercially available branded versions are in short supply.

At TrimRx, we connect our members with healthcare providers who can prescribe these compounded formulations when appropriate. For readers who want added nutritional support during GLP-1 treatment, the GLP-1 Daily Support supplement may be a helpful companion.

Note: Compounded medications provide an alternative pathway to access these molecules, but they should always be sourced from reputable pharmacies and used under the guidance of a licensed healthcare provider.

For energy support during weight loss, the Weight Loss Boost supplement is another option to consider.

How GLP-1 Medications Are Prescribed Today

The process for starting a GLP-1 medication has changed significantly since 2005. It used to require frequent in-person visits to a specialist. Today, telehealth platforms have made it much easier for eligible individuals to receive a medical evaluation and a personalized treatment plan.

We provide a streamlined approach to this process. Because these are prescription medications, they require a thorough medical screening to ensure they are safe and appropriate for your specific health profile.

The Path to Starting Your Program

Step 1: Complete an initial health assessment. You will fill out a detailed quiz that covers your medical history, BMI, and weight loss goals. This information is essential for the provider to determine if you are a candidate for GLP-1 therapy. When you’re ready to begin, take the free assessment quiz.

Step 2: Undergo a clinical evaluation. A licensed healthcare provider reviews your assessment and, if necessary, orders lab work to check your metabolic health. This ensures the medication is a safe fit for your body.

Step 3: Receive your personalized treatment plan. If the provider determines you are eligible, they will issue a prescription. This plan includes the appropriate medication, whether it is an injectable or an oral format, tailored to your needs.

Step 4: Ongoing support and shipping. The medication is shipped directly from a partner pharmacy to your door. You receive ongoing support from a team of specialists to help you manage side effects and track your progress.

Why the Approval Timeline Matters

Looking back at the timeline from 2005 to 2023 shows that these medications are not “fad” drugs. They have been studied for nearly twenty years in the context of Type 2 diabetes and for a decade in the context of weight management. This long history provides a wealth of data on their safety profile and long-term effectiveness.

The progression from daily injections to weekly doses, and from single-hormone targets to dual-hormone targets, shows a commitment to improving the patient experience and clinical outcomes. This history is why healthcare providers feel confident recommending these treatments as part of a comprehensive weight loss program.

That long history also helps explain why weight loss plateau on semaglutide is a normal part of treatment rather than proof that the medication failed.

Bottom line: The long timeline of FDA approvals for GLP-1 medications demonstrates a steady evolution in safety and efficacy, transforming weight management from a lifestyle struggle into a manageable medical condition.

Is a GLP-1 Medication Right for You?

While the history of these medications is impressive, the most important question is whether they fit your personal health journey. Not everyone is a candidate for GLP-1 therapy. These medications are typically intended for individuals who have a BMI over 30, or a BMI over 27 with an associated health condition such as hypertension or high cholesterol.

They are also meant to be used alongside healthy lifestyle changes. When combined with a balanced diet and regular physical activity, GLP-1 medications can help reset the body’s natural hunger signals, making it easier to stick to a sustainable plan.

If you have tried traditional weight loss methods without success, it may be time to consider the metabolic support that modern science offers. Our platform was designed to bridge the gap between clinical expertise and your daily life, providing the tools and professional guidance necessary for long-term success.

The TrimRx Approach to Sustainable Weight Loss

At TrimRx, we understand that weight loss is a deeply personal and often emotional process. Our mission is to provide a science-backed, empathetic framework that helps you take control of your metabolic health. We combine the power of clinically studied medications with a telehealth-first model that removes the barriers to high-quality care.

Our programs are fully personalized, acknowledging that every individual’s biology is unique. Whether you are just starting to research GLP-1 medications or are ready to begin a supervised program, we are here to guide you through every step of the timeline.

Key Takeaway: Sustainable weight loss is about more than just a number on the scale; it is about improving your overall metabolic health and quality of life through a personalized, medically supervised approach.

FAQ

What was the first GLP-1 drug ever approved?

The first GLP-1 receptor agonist approved by the FDA was exenatide, known by the brand name Byetta, in April 2005. It was originally approved to help manage blood sugar in adults with Type 2 diabetes and required twice-daily injections.

When did the FDA approve a GLP-1 drug specifically for weight loss?

The first GLP-1 drug approved specifically for chronic weight management was Saxenda® (liraglutide) in December 2014. Before this, these medications were only officially approved for the treatment of Type 2 diabetes, although weight loss was a frequently observed side effect.

Is Ozempic approved for weight loss?

Ozempic® is FDA-approved specifically for the treatment of Type 2 diabetes to improve blood sugar control. However, the same molecule (semaglutide) is approved for weight loss under the brand name Wegovy®, which generally uses a higher weekly dose. For a closer look at semaglutide treatment, what semaglutide injections are and how they can help you is a helpful companion read.

Why are there different brand names for the same medication?

Pharmaceutical companies often use different brand names to distinguish between the intended uses of the drug. For example, tirzepatide is called Mounjaro® when used for Type 2 diabetes and Zepbound® when used for chronic weight management, though the underlying active ingredient is the same.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.